Structure based drug discovery by virtual screening of 3699 compounds against the crystal structures of six key SARS-CoV-2 proteins

CURRENT STATUS: Posted

Shoab Saadat, Salman Mansoor, Naveen Naqvi, Ammad Fahim, Zaira Rehman, Shahar Yar Khan, Sidra Saadat

Shoab Saadat
Department of Nephrology, Mid and South Essex NHS Foundation Trust, UK
dr.shoaibsaadat@gmail.com Corresponding Author
ORCiD: https://orcid.org/0000-0002-8643-4787

Salman Mansoor
Department of Neurology, Sligo University Hospital, Sligo, Ireland

Naveen Naqvi
Department of Oncology, Shifa International Hospital, Islamabad, Pakistan

Ammad Fahim
Department of Multidisciplinary Sciences, National University of Medical Sciences, Islamabad, Pakistan

Zaira Rehman
Atta ur Rahman School of Applied Biosciences, National University of Sciences and Technology (NUST), Islamabad, Pakistan

Shahar Yar Khan
Ysbyty Gwynedd, Bangor, NHS Trust, UK

Sidra Saadat
Rawalpindi Medical University, Rawalpindi, Pakistan
Subject Areas

Molecular Biology  Biochemical Research Methods

Keywords

SARS-CoV-2, Drug discovery, COVID-19 Pandemic, Molecular docking, Computational Docking, PLpro, 3CLpro, NSP9, NSP10-16, Coronavirus, Herbal Medicine, Antivirals, Virtual screening
Abstract

Background

The current Novel Coronavirus (SARS-CoV-2) pandemic is the third major outbreak of the 21st century which emerged in December 2019 from Wuhan, China. At present there are no known treatments or vaccines to cure or prevent the illness.

Objective

The objective of this study was to explore a list of potential drugs (herbal and antivirals) for their role in inhibiting activity and or replication of SARS-CoV-2 by using molecular docking onto the crystal structures of key viral proteins.

Methodology

In this study, we used molecular docking to estimate the binding affinities of 3699 drugs on the potential active sites of the 6 main SARS-CoV-2 proteins (Papain like protease, Main protease, ADP Ribose phosphatase, Spike protein, NSP-9 and NSP-10 to 16 complex). While other studies have mostly been performed on the homology models, we obtained the most recently submitted crystal structures of all 6 proteins from the protein data bank for this analysis.

Results

Our results showed the top ligands as Theasinensin A, Epigallocatechin, Theaflavin, Theasinensin A, Epigallocatechin and Favipiravir showing the highest binding affinities against papain-like protease, ADP ribose phosphatase, main protease, spike protein, RNA replicase (NSP-9) and methyl-transferase (NSP-16) respectively.

Conclusion

We show that the compounds from our list with the greatest inhibitory potential against SARS-CoV-2 activity or replication include Theasinensin A, Epigallocatechin-3-gallate, Theaflavin, Favipiravir, Curcumin, Quercetin, Mitoxantrone, Amentoflavone, Colistin, Cimicifugic acid, Theaflavin, Silymarin and Chebulagic. We recommend further wet-lab and clinical testing of these compounds to further explore their role against SARS-CoV-2.

1. Introduction

1.1 Background

The beginning of the 21st Century has seen two major Coronavirus related outbreaks. These include Severe acute respiratory syndrome (SARS-CoV; 2002–2003), Middle East respiratory syndrome (MERS-CoV; 2012) (1). The current Novel Coronavirus (SARS-CoV2) or COVID-19 illness is the third major outbreak which emerged in December 2019 from Wuhan, China (2). The significant mortality associated with the illness and its rapid transmission rate has caused a global health crisis. The mortality rate that was estimated on the 3rd of March by the World Health Organization (WHO) was 3.4% (3). At present there are no known treatments or vaccines to cure or prevent the illness.

1.2 Phylogenetics and Taxonomy of SARS-CoV-2

The recent SARS-CoV2 belongs to a family of Coronaviruses (CoVs) which are further subclassified into four genera 1) Alpha-CoV, 2) Beta-CoV, 3) Gamma-CoV and 4) Delta-CoV (4). It is similar in its subgenus belonging to Sarbecovirus (beta-CoV lineage B) like its previous predecessor (SARS-CoV; 2002–2003) (5), (6).

1.3 Biological Structure
Coronaviruses (CoVs) have an enveloped positive ribonucleic acid (RNA) genome (7). The positive-sense single stranded RNA (+ssRNA) virus has a single linear RNA segment (7). The genome sequencing as of late 27th march 2020 has yielded 1,495 SARS-CoV-2 genomes (8). In addition to this, there are four different viral proteins that are common in CoVs among others which include 1) M proteins, 2) S-Proteins, 3) E-Proteins and 4) N-Proteins (9).

1.4 Structure Based Drug discovery

There are two common ways among others in which drugs can modulate the course of a viral disease activity: 1) Effects on the human immune response and 2) The direct inhibitory effects on the viral activity / replication by binding to specific protein sites.

It is difficult to gauge the effects of immune response due to the complex interplay of different immune pathways and usually takes time to be discovered, however, the latter is possible early in the disease epidemiological course by computational modeling and wet lab tests. The true efficacy and side effects profile however can only be determined in a clinical setting such as by a randomized controlled trial.

Computational modeling provides a way to simulate a compound’s interaction with a given viral protein using molecular docking. Such a docking model can be used as a precursor for potential drug discovery. In order to discover a potential drug there are two types of virtual screenings which are usually performed. Structure based and Ligand based. We used the former method to screen a large list of potential inhibitory ligands against 6 main viral proteins.

1.5 Objective

The objective of this study hence was to explore a list of potential drugs (herbal and antivirals) for their role in inhibiting activity and replication of SARS-CoV-2 by using molecular docking onto the crystal structures of key viral proteins.

2 Methods

2.1 Data collection

2.1.1 Selecting the main SARS-CoV-2 viral proteins from protein data bank

The protein data bank was searched for the most recently resolved crystal structures submitted related to SARS-CoV-2 virus (10). A total of 114 submissions were found (date: 14th April 2020). Out of the total, 105 structures were resolved using X-RAY diffraction method while 81 structures from this subset had a resolution less than 3Å. Since our candidate proteins were not all resolved by other methods including cryo electron microscopy or Nuclear magnetic resonance spectroscopy (NMR) thus in order to keep it consistent over all the proteins, we selected x-ray diffraction to be the only method of choice. This was the final subset which was used to find the most recently submitted structures for papain-like protease (PLpro) (PDB code 6w9c), NSP-15 endonuclease (PDB code 6vww), spike protein complexed with ACE receptor (PDB code 6m0j), main protease (Mpro) (PDB code 5rek), NSP-3 in complex with AMP (PDB code 6w6y), NSP-9 RNA replicase bound to peptide molecule (PDB code 6w9q), NSP-10 to NSP-16 complex (PDB code 6w75) [Table 1] [Fig 2].

SARS-CoV-2 genome consists of ORF1a sequence of about 14 kilobase long which encodes for polypeptide 1a which is eventually cleaved to produce the two replicate proteins namely PLpro (NSP-2-3) and 3CLpro (NSP-5). By ribosomal frameshifting, the virus also encodes for polypeptide 1ab which contains the RNA polymerase (NSP-12), helicase (NSP-13), exonuclease (NSP-14), endoribonuclease (NSP-15) and methyl-transferase (NSP-16) domains (11). These molecules were selected because each of them is found to play a critical role in either viral entry or replication in the human host. Some of the submissions (NSP-15, spike protein, Mpro, NSP-3, NSP-16) were found to be complexed with existing ligands which provided clues for potential receptor sites while for PLpro, literature review and docking-site search algorithm were used to help in potential receptor site identification. There have been previous studies testing several potential ligands against some of the mentioned
proteins (PLpro and Mpro) but most of them have been performed on the homology modelled protein structures (12,13). We used the X-RAY diffraction resolved structures because they are the closest representations of the true protein structure.

Table 1. Selected protein molecules for docking experiment

| No | Protein                                      | PDB code | Resolution (Å) | Main Ligand(s)                                      | Release Date |
|----|----------------------------------------------|----------|----------------|-----------------------------------------------------|--------------|
| 1  | Papain-like protease (PLpro)                 | 6w9c     | 2.7            | -                                                   | 1/4          |
| 2  | NSP-15 endonuclease                          | 6vww     | 2.2            | Glycerol, Acetic acid                                | 4/3          |
| 3  | Spike protein                                | 6m0j     | 2.45           | ACE receptor 2                                       | 18,          |
| 4  | Main protease (Mpro / 3CLpro)                | 5rek     | 1.74           | 1-{4-[(3-fluorophenyl)sulfonyl]piperazin-1-yl}ethan-1-one | 25;          |
| 5  | NSP-3 in complex with AMP                    | 6w6y     | 1.45           | Adenosine Monophosphate, 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | 25,         |
| 6  | NSP-10 to NSP-16 complex                     | 6w75     | 1.95           | S-Adenosylmethionine                                 | 25,          |

2.1.2 Searching the compound database for the potential herbal and antiviral ligands

We obtained a list of more than 3457 potential antiviral phytochemicals and traditional Chinese medicinal compounds through a thorough search on Pubchem, Chembl and Zinc databases (20,21). Several freely available online databases (MPD3, MAPS) specializing in medicinal drugs were also used for the purpose of drug selection (22–24). After literature review, we also ran a separate CHEMBL search query using search strings “antiviral” and “antiviral medications”. The query resulted in a total of 2350 compounds. We then filtered the results by choosing only small molecules and ligands with RO5 violations less than 2 (Lipinski’s rule of five) to keep the most orally active drug-like agents selected. This resulted in a final selection of 242 antiviral medications which were added to our final drug table. The resultant number of the total ligands for the final docking experiment was 3699 [Fig 2].

2.2 Molecular docking

First, all the candidate protein structures were analysed for sequence completion. Then, literature review was performed for each in order to select the potential docking sites. If the crystal structure already came with an attached ligand [Table 1], the site of ligand attachment was selected for subsequent docking, else (NSP-16), the ligand-binding pockets are determined based on a transformation of the Lennard-Jones potential by convolution with a Gaussian kernel of a certain size, a grid map of a binding potential and construction of equipotential surfaces along the maps (ICM pro version 3.8-7c) (25,26). Once the candidate pockets were listed, the pocket with the highest buriedness, hydrophobicity and drug-likeness was selected [Fig 15] (27). After selecting the target pocket, structure-based virtual screening method was used for ligand docking procedure. Using Intel i7 8750 processor (ICM pro version 3.8-7c, MolSoft LLC, San Diego, CA, USA), Biased probability Monte Carlo (BPMC) procedure was used to perform conformational sampling of the ligand table against the selected receptor pocket with 2 conformer samples being generated for each ligand (28). An all-atom vacuum force field ECEPP/3 with appended terms to account for solvation free energy and entropic contribution was used for the
final binding affinity score calculation (29). Visual iNSP-ection was done to identify the compounds which are outside the receptor or weekly binding. From the subsequent list, ligand conformations with the lowest overall ICM and mfscores were selected for the final reporting. As per ICM’s user manual, an ICM score of <-32 or a mfscore <-100 is considered to reflect a high binding affinity (30).

3 Results And Discussion

3.1 Papain-like Proteinase (PLpro, NSP-2-3) (PDB code 6w9c)

PLpro is responsible for cleavaging the N-terminus of the replicase polyprotein and thus production of NSP-1-3. This way it plays an important role in viral replication. It is also shown to be suppressing type 1 interferon signalling thus compromising the host immunity (31). For all these reasons, it is a valuable target for inhibiting viral replication.

We first performed amino acid sequence alignment between the selected new crystal structure (PDB code 6w9c) and its closest match in humans SARS-CoV PLpro (PDB code 3e9s). There was a high sequence identity of about 82% with several conserved regions [Fig 3].

In order to find the docking site, we used the above information of highly conserved sites and an existing PDB crystal structure containing a bound ligand called 5-Amino-2-Methyl-N-[(1r)-1-Naphthalen-1-Ylethyl]benzamide (an engineered hydrolase of class: papain-like protease deubiquitinase inhibitor) (32) locked in with the crystal structure of SARS CoV-1 PLpro (PDB code 3e9s) (33).

We then performed structural residue alignment. The cartesian RMSD value between the new SARS-CoV-2 PLpro and earlier reported SARS-CoV PLpro came out to be 1.48 which shows a close structural similarity between the two structures [Fig 4]. It also implies that the ligand binding site identified in the later can be used for the new crystal structure of SARS-CoV-2 as well. The ligand receptor site was thus selected by analysing this existing crystal structure (A-chain) and its attached ligand. This site was prepared by adding hydrogen ions, electrostatic charges and removing water molecules.

The screening results were plotted with ICM score on x-axis while the mfscore was on y-axis. This provided the best selection of ligands which performed equally well on both scoring systems [Fig 5].

The results are displayed in Table 2 which shows a selection of lowest scoring ligands on ICM and mfscores.

It was found that Theasinensin A which is a polyphenol flavonoid found in black tea (Camellia sinensis) happened to score the lowest. It was found to be surrounded by 9 amino acid residues in the pocket with G266 being the closest with a distance between it and the ligand’s oxygen-8 calculated to be around 2.9 Å. The ligand was also forming at least 1 more hydrogen bond with E161 and several hydrophobic interactions (D164, L162, P248, Y264, N267, G163, K157) [Fig 6].

Curucumin (principal curcuminoid of turmeric), Quercetin (found in red onions and kale), Mitoxantrone (an anthracenedione antineoplastic agent), Amentoflavone (a biflavonoid constituent of a number of plants including Ginkgo biloba) and Colistin (an antibiotic for multi-resistant gram-negative bacteria) were some of the most notable ligands with high affinity towards the receptor pocket.

Table 2. Potential PLpro inhibitors from the curated database of herbal and antiviral drugs.
3.2 ADP Ribose phosphatase macro domain of NSP-3 SARS-CoV-2 (PDB code 6vww)

Coronaviridae (genera Coronavirus and Torovirus) possess one of the largest single-stranded RNA genomes (27 to 31.5 kb) (34). One of the non structural proteins made by polypeptide 1a of SARS-CoV-2 is NSP-3 which contains certain well preserved macro domains (35). One such domain has been identified as ADP ribose phosphatase which is believed to be involved in diverse pathways, including ADP-ribose metabolism and posttranslational protein modification. The SARS NSP-3 domain readily removes the 1'' phosphate group from Appr-1''-p in in vitro assays, confirming its phosphatase activity (36).

We screened multiple potential ligands against the AMP binding site of this protein [Fig 7].

The results show [Table 3] that Epigallocatechin gallate, also known as epigallocatechin-3-gallate (most abundant catechin in tea) came on top with the highest ICM score and shows very high promise in binding this active receptor site. This drug has been shown to be effective in treatment of colon cancer cells as well (37) and is known for its antioxidant properties. The ligand was shown to be forming 6 hydrogen bonds (G46, A50, G47,
S128, W360, A129) with the closest one with G46 (distance 2.6 Å) [Fig 8]. There were also several hydrophobic interactions as well (I131, A38, G130, F132, G48).

The second notable mention is of Cimicifugic acid (extracted from cimicifuga racemosa). Its role has been well documented in preventing collagen degradation by collagenases or collagenolytic enzymes under pathological conditions, wound healing, or inflammation (38). Its role has also been documented for its antiviral activity against enterovirus A71 infection (39).

Table 3. Potential NSP-3 inhibitors from the curated database of herbal and antiviral drugs.
The protein crystal structure used in this analysis represents the PanDDA analysis of the crystallographic fragment screening of SARS-CoV-2 main protease A-chain. The structure came with a ligand molecule docked

### 3.3 Main protease (Mpro also called 3CL pro) (PDB code 6w6y)

| No | Molecule   | Name        | ICM Score | Number of Atoms | mfScore |
|----|------------|-------------|-----------|-----------------|---------|
| 1  | ![Epigallocatechin](image1.png) | Epigallocatechin | -43.68 | 36 | -18.76 |
| 2  | ![Scutellarein](image2.png) | Scutellarein | -41.21 | 31 | -43.38 |
| 3  | ![Amentoflavone](image3.png) | Amentoflavone | -40.94 | 58 | -51.50 |
| 4  | ![Myricetin](image4.png) | Myricetin | -40.59 | 33 | -41.57 |
| 5  | ![Cimicifugic](image5.png) | Cimicifugic | -36.47 | 50 | -96.24 |
| 6  | ![Quercetin](image6.png) | Quercetin | -36.43 | 32 | -52.35 |
around the active catalytic site. This site was subsequently selected for a further docking experiment. Mpro along with PLpro is considered an essential protein for SARS-CoV-2 replication and forms a part of the replicase polyprotein complex. It is found to operate at at-least 11 active cleavage sites on the large polyprotein 1ab (~790 kDa). If the action of this protein is blocked, it would most certainly hinder the replication of this virus. After literature review and using the ligand position that came with the crystal structure, the protein receptor site was identified. It was made sure that the receptor site also includes Cys145 and His41 (catalytic dyad) which are the main amino acid residues of the active catalytic site.

The ligands with the lowest scores on ICM and mfscore scales included Theaflavin, 5,7,3',4'-Tetrahydroxy-2'-{(3,3-dimethylally and Silymarin. This is shown in Fig 9 and Table 4].

Table 4. Potential Mpro inhibitors from the curated database of herbal and antiviral drugs.
Theaflavin, an antioxidant polyphenol which is often formed from the condensation of flavan-3-ols in tea leaves, had the lowest ICM score of -25. Theaflavin and its derivatives have also been shown to be equally effective as

| No | Molecule | Name | ICM Score | Number of Atoms | mfScore |
|----|----------|------|-----------|-----------------|---------|
| 1  | ![Theaflavin](image1.png) | Theaflavin | -25.07 | 44 | -78.32 |
| 2  | ![Silymarin](image2.png) | Silymarin | -23.86 | 57 | -110.89 |
| 3  | ![5,7,3',4'-Tetrahydroxy-2'- (3,3-dimethylally](image3.png) | 5,7,3',4'-Tetrahydroxy-2'- (3,3-dimethylally | -22.18 | 44 | -93.65 |
| 4  | ![Scutellarein](image4.png) | Scutellarein | -21.04 | 31 | -68.50 |
| 5  | ![Astragal](image5.png) | Astragal | -18.58 | 52 | -78.75 |
| 6  | ![Viridiflorin](image6.png) | Viridiflorin | -15.30 | 51 | -81.79 |
an antioxidant in comparison with catechins (40). Furthermore, it was shown to have lower docking scores against RNA dependent RNA polymerase of SARS-CoV-2 in a recent study (41). Though the most important finding was a strong hydrogen bond between its hydrogen (H8) and oxygen of His41 residue which also serves a critical role in forming the active catalytic site. Cys145 was also in close proximity, involved in hydrophobic interactions, thus the ligand was able to fully block this active catalytic site. Apart from these, Theaflavin was forming a total of four more strong hydrogen bonds (T26, T24, Q189, S46) with the closest being 2.7Å in distance. [Fig 9]. There were also several hydrophobic interactions (M49, T25, T45).

The second most interesting ligand was Sillymarin as it had equally low ICM and mfscore. It is known mostly for its hepatoprotective functions, but recently has been shown possessing antiviral properties against hepatitis C virus (42). Sillymarin is a standardized extract of the milk thistle seeds, containing a mixture of flavonolignans (43) and has also been shown to exert membrane-stabilizing and antioxidant activity (44). It also possesses antifibrotic, immunomodulating and anti-inflammatory effects as mentioned in another study (45). Our findings suggest that these two ligands can act as potential viral Mpro inhibitors of SARS-CoV-2 and can be selected for subsequent testing.

3.4 Spike Protein (PDB code 6m0j)

The selected viral protein crystal structure represents the main interaction site of SARS-CoV-2 spike protein bound with human ACE-2 receptor (hACE2). For our target receptor site for docking, we chose the hACE2 interaction domain on the spike protein (receptor binding domain). Spike protein is considered to be the key for entry into the body cells. It has been shown to be interacting with hACE2 receptors on several human cells including type-2 pneumocytes and enterocytes where it helps in the protein mediated membrane fusion (46). It has also been shown to infect T lymphocytes despite a low expression of hACE2 receptors (47). Thus by blocking this receptor binding domain by a ligand, we can potentially inhibit its entry into human cells.

The docking results showed C20H19F2N3O5 (Dolutegravir) with the lowest ICM score of -19.29 while Chebulagic had the lowest mfscore of -133.7 [Table 5]. The ligands with equally good scores on both scales included Theasinensin with an ICM score of -19.22 and an mfscore of -98 and Colistin (ICM score -16.69, mfscore -126) [Fig 11].

Table 5. Potential spike protein inhibitors from the curated database of herbal and anti-viral drugs.
The chosen ligand (Theasinensin A) showed about 3 different hydrophobic interactions (Y505, Y495, G496) while it formed close hydrogen bonds with 6 residues (T500, Q498, Y449, G502, N501, R403) [Fig 12] with the closest

| No | Molecule | Name         | ICM Score | Number of Atoms | mfScore |
|----|----------|--------------|-----------|-----------------|---------|
| 1  | C20H19F2N3O5 | -19.29       | 49        | -37.62          |
| 2  | Theasinensin | -19.22       | 100       | -98.12          |
| 3  | Ladanein  | -17.60       | 37        | -7.76           |
| 4  | Colistin  | -16.69       | 179       | -126.29         |
| 5  | Curcumin  | -16.51       | 47        | -26.32          |
| 6  | Theaflavin | -16.27       | 44        | -21.34          |
having a distance of 2.47Å from T500. Theasinensin A is among those herbal agents which have already been shown to possess antiviral activity (48).

3.5 RNA Replicase NSP-9 (PDB code 6w9q)

Non structural protein 9 has been found to be playing a key role in binding of RNA-Polymerase to the RNA strand and interacts with NSP-8, thus forming an important component of the RNA-polymerase complex (49). Inhibiting its action may play a role in keeping the RNA-polymerase from binding to the RNA strand thus inhibiting the viral replication. The receptor pocket for action was chosen to be around the bound peptide site of the crystal structure. This was then verified by the pocket finder screening results of the ICM software which proved the selected pocket to be showing maximum hydrophobicity and receptivity for a drug like ligand.

Our docking results showed Epigallocatechin with the lowest ICM score of around -26 while Chebulagic, a benzopyran tannin, had the lowest mfscore of -117 [Fig 13 and Table 6]. Epigallocatechin (found in black tea) has been shown to be an effective antioxidant in several studies (50) while Chebulagic acid has been shown to be inhibiting enterovirus 71 replication in some studies (51). Cimicifugic acid, Scutellarin and Rosemarinic acid were other compounds with lower ICM and mfscores. Epigallocatechin is also found to have a similar zinc ionophore activity as shown by chloroquine in one of the studies (50) thus being a herbal agent, it can be safely used in higher concentrations to achieve better inhibition compared to chloroquine.

Epigallocatechin had the lowest overall score in both metrics. It was shown to be forming 2 hydrophobic interactions (T77, V76) and 4 hydrogen bonds (R111, D78, A107, V110) with the smallest distance of 2.8Å with R111 [FIG 14].

Table 6. Potential NSP-9 inhibitors from the curated database of herbal and antiviral drugs.
These results show the potential role of these ligands in inhibiting NSP-9 thus they may hinder RNA replication.

| No | Molecule | Name         | ICM Score | Number of Atoms | mfScore |
|----|----------|--------------|-----------|-----------------|---------|
| 1  |          | Epigallocatechin | -26.68    | 36              | -11.13  |
| 2  |          | C12H21N      | -17.80    | 34              | -11.10  |
| 3  |          | Cimicifugic  | -16.45    | 50              | -29.98  |
| 4  |          | Ladanein     | -14.80    | 37              | -49.48  |
| 5  |          | Mitoxantrone | -14.62    | 60              | -69.33  |
| 6  |          | Scutellarein | -14.34    | 31              | -58.20  |
3.6 Non structural proteins 10-16 (PDB code 6w75)

NSP-10-16 is a complex of several individual proteins including RNA polymerase (NSP-12), helicase (NSP-13), exonuclease (NSP-14), endoribonuclease (NSP-15) and methyl-transferase (NSP-16) domains. Each one plays its role in bringing about the replication of the virus. The ICM pocket finder was run on this complex to locate the most suitable target pockets for ligand docking [Fig 15]. The selected pocket was found on the A-chain of NSP-16 molecules that had the highest hydrophobicity and DLID scores (Drug-Likeness) (27) and a volume of 348A³.

After selecting the target pocket, virtual screening was performed [Fig 16] which showed the antiviral Favipiravir (Avigan) a novel RNA polymerase inhibitor having the highest affinity (ICM score -36, mfscore -42) with receptor site [Table 7]. Favipiravir is a novel broad-spectrum antiviral drug and has been found to be effective against all the subtypes of influenza virus including those resistant to neuraminidase and M2 inhibitors (52). In a recently published study it was found to be reducing viral infection (53).

Table 7. Potential NSP-16 inhibitors from the curated database of herbal and antiviral drugs.
Favipiravir was developed by Fujifilm Toyama Chemical and approved in Japan in 2014 for the treatment of influenza and is currently under trial for its potential role in inhibiting viral replication of SARS-CoV-2. In our

| No | Molecule | Name     | ICM Score | Number of Atoms | mfScore |
|----|----------|----------|-----------|-----------------|---------|
| 1  | ![Favipiravir](image1.png) | Favipiravir | -36.04    | 15              | -42.26  |
| 2  | ![Amentoflavone](image2.png) | Amentoflavone | -33.10    | 58              | -117.57 |
| 3  | ![C8H12N4O5](image3.png) | C8H12N4O5 | -30.63    | 29              | -26.44  |
| 4  | ![Baicalein](image4.png) | Baicalein | -29.87    | 30              | -66.20  |
| 5  | ![Cimicifugic](image5.png) | Cimicifugic | -29.28    | 50              | -109.06 |
| 6  | ![Scutellarein](image6.png) | Scutellarein | -28.06    | 31              | -67.88  |
analysis, it was found to be making 5 hydrophobic interactions (D6897, D6898, D6912, M6929, F6947) while it was forming 4 hydrogen bonds (G6869, G6911, C6913, S6896) with the closest one of 2.8Å with G6869 [Fig 17].

Among other ligands, Amentoflavone (a biflavonoid constituent of a number of plants including Chinese plant Selaginella tamariscina and Ginkgo biloba) also showed a high affinity with an ICM score of -33. It has been shown to possess antiviral and anti cancer effects in some studies (54,55). Theaflavin was also among potential inhibitors of this site.

The following table summarizes the key ligands found for all 6 proteins [Table 8].

Table 8. Summary The most potent compounds with their relative binding force scores, immune effects and sources

| Proteins | Drugs       | ICM score | mfScore | Immune effects                                                                 | Viral Effects                  |
|----------|-------------|-----------|---------|--------------------------------------------------------------------------------|-------------------------------|
| PLpro    | Theasinensin A | -32.25    | -119.14 | Reduces the levels of pro-inflammatory mediators (56)                          | May have antiviral effects (57)|
|          | Curcumin    | -24.23    | -24.41  | Reduces the levels of Proinflammatory Cytokines (58)                           | May have antiviral effects (59)|
|          | Quercetin   | -21.06    | -58.94  | Can Reduce the LPS-induced macrophage inflammation (60)                        | May have antiviral effects (61)|
| Mitoxantrone | -22.83    | -91.00    |         | No significant effects on proinflammatory cytokines (62)                      | May have antiviral effects (63)|
|          | Amentoflavone | -23.21    | -91.43  | Reduces proinflammatory cytokines (64)                                         | May have antiviral effects (65)|
|          | Colistin    | -11.42    | -168.50 | Increases the secretion of proinflammatory cytokines (66)                     | Not Known                      |
| ADP Ribose | Epigallocatechin | -43.68    | -18.75  | Reduces proinflammatory cytokines (67)                                         | May have antiviral effects (68)|
|          | Cimicifugic acid | -36.47    | -96.23  | Reduces proinflammatory cytokines (69)                                         | May have antiviral effects (39)|
| Substance        | Change (µM) | Change (nM) | Effect Description                                                                 | Notes                                      |
|------------------|-------------|-------------|-----------------------------------------------------------------------------------|--------------------------------------------|
| **Mpro**         |             |             |                                                                                   |                                            |
| Quercetin        | -36.43      | -52.34      | Can Reduce the LPS-induced macrophage inflammation (60)                           | May have antiviral effects (61)           |
| Theaflavin       | -25.07      | -78.31      | Reduces proinflammatory cytokines (70)                                             | May have antiviral effects (71)           |
| Silymarin        | -23.86      | -110.89     | Reduces proinflammatory cytokines (72)                                             | May have antiviral effects (42)           |
| **Spike protein**|             |             |                                                                                   |                                            |
| Theasinensin A   | -19.21      | -98.12      | Reduces the levels of pro-inflammatory mediators (56)                              | May have antiviral effects (57)           |
| Chebulagic       | -12.95      | -133.70     | Reduces proinflammatory cytokines (73)                                             | May have antiviral effects (74)           |
| Dolutegravir     | -19.28      | -37.62      | Not Known                                                                          | Known anti-retroviral used in HIV (75)   |
| Colistin         | -16.69      | -126.28     | Increases the secretion of proinflammatory cytokines (66)                          | Not Known                                 |
| **NSP-9**        |             |             |                                                                                   |                                            |
| Epigallocatechin | -26.68      | -11.13      | Reduces proinflammatory cytokines (67)                                             | May have some antiviral properties (68)   |
| Chebulagic       | -16.45      | -29.97      | Reduces proinflammatory cytokines (73)                                             | May have antiviral effects (74)           |
| **NSP-16**       |             |             |                                                                                   |                                            |
| Favipiravir      | -36.04      | -42.26      | Reduces proinflammatory cytokines (76)                                             | Known antiviral with variable spectrum against viruses (7) |
| Amentoflavone    | -33.1       | -117.56     | Reduces proinflammatory cytokines (64)                                             | May have antiviral effects (65)           |
### 3.7 Comparison with other classes as controls

We also tested some of the most mentioned (12,78–81) ligands from different drug classes (Antivirals, Antibacterials, Antifungals, Antimalarials, Antihypertensive, Cholesterol lowering, Anticancer, Antiallergics, Antiinflammatory and membrane stabilizers) as controls for each of the protein targets. Favipiravir and Ribavirin in general, Atoquone and Rosuvastatin against NSP-3, Mitoxantrone against PLpro, Montelukast against Spike protein and Silymarin against NSP-3 and NSP-16 showed high binding affinities (Table 9). However, as mentioned above, most of these control ligands did not score the best affinity scores when compared to other phytochemicals in each protein receptor docking experiment except for Favipiravir.

Table 9. Shows the comparative ICM scores of some of the most representative ligands from different classes tested as controls against the phytochemicals.
## 4 Conclusion

Using structure based ligand screening method, we identified Theasinensin A (for PLpro and spike protein), Epigallocatechin (for ADP ribose phosphatase), Theaflavin (for Mpro) and Favipiravir (for NSP-16) as the key probable inhibitors for their respective receptor protein pockets. Furthermore, there were few drugs that bound with more than one protein with low mfscores (Theasinenis A with PLpro and spike protein, Quercetin with PLpro and ADP ribose phosphatase, Amentoflavone with PLpro and NSP-16, Cimicifugic acid with ADP ribose phosphatase and NSP-16, Chebulagic with spike protein and NSP-9). This may suggest their role in viral inhibition by more than one mechanism of action.

Based on the finding of our study, we suggest further analysis of our selected potential ligands in a wet-lab or clinical setting in order to validate our findings.

| Ligands         | PLPro  | NSP-3  | Mpro  | Spike-Pro | NSP-9  |
|-----------------|--------|--------|-------|-----------|--------|
| Favipiravir     | -14.80 | -18.52 | -9.51 | -11.17    | -11.18 |
| Ribavirin       | -14.01 | -30.33 | -8.77 | -10.16    | -9.31  |
| Darunavir       | -12.29 | -8.82  | -10.41| -7.06     | 0.69   |
| Ritonavir       | -5.04  | 2.82   | 4.63  | -4.74     | 6.86   |
| Saquinavir      | -5.94  | -8.78  | -14.31| -13.19    | 0.18   |
| Remdesivir      | -2.33  | -8.23  | -6.49 | -2.23     | 2.15   |
| Azithromycin    | 7.41   | 31.1   | 5.34  | 1.27      | 7.72   |
| Colistin        | -11.42 | 11.44  | 0.33  | -16.69    | 27.99  |
| Prulifloxacin   | -14.44 | -14.69 | -13.32| -8.80     | -6.84  |
| Atovaquone      | -12.04 | -29.46 | -10.44| -7.25     | -9.83  |
| Artemisinin     | -8.26  | 2.77   | -5.12 | -4.80     | -7.28  |
| Chloroquine     | -6.75  | -11.61 | -8.37 | -2.30     | -14.03 |
| Hydroxychloroquine | -4.66  | -9.54  | -10.33| -6.19     | -4.60  |
| Ramipril        | 1.43   | -20.20 | -8.30 | -7.02     | -6.91  |
| Rosuvastatin    | 4.10   | -33.45 | -7.47 | -13.15    | -7.45  |
| Mitoxantrone    | -22.83 | -15.99 | -6.50 | -12.63    | -14.62 |
| Daunorubicin    | -13.00 | -12.41 | -2.78 | -11.20    | -3.66  |
| Montelukast     | -17.02 | -11.87 | -17.9 | -20.24    | -18.04 |
| Silymarin       | -11.88 | -29.79 | -23.86| -5.53     | -4.50  |
5 Declarations

- Ethics approval and consent to participate: Not Applicable
- Consent to publish: Not Applicable
- Availability of data and materials
- Competing interests: All authors declare no competing interests
- Funding: No funding was received at any point
- Authors' Contributions: SS, SM, NN were involved in the writing, drafting, data analyzing of this manuscript. AF, ZR, SYK, SS gave critical input for finalizing the manuscript
- Acknowledgements: Not applicable

6 Appendix

Per the authors, there is no information for this section.

7 References

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012 Nov 8;367(19):1814–20.
2. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.
3. Coronavirus Mortality Rate (COVID-19) - Worldometer [Internet]. [cited 2020 Apr 18]. Available from: https://www.worldometers.info/coronavirus/coronavirus-death-rate/#ref-13
4. Lefkowitz EJ, Dempsey DM, Hendrickson RC, Orton RJ, Siddell SG, Smith DB. Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV). Nucleic Acids Res. 2018 Jan 4;46(D1):D708–17.
5. auspice [Internet]. [cited 2020 Apr 18]. Available from: https://nextstrain.org/groups/blab/sars-like-cov
6. Wong ACP, Li X, Lau SKP, Woo PCY. Global epidemiology of bat coronaviruses. Viruses. 2019 Feb 20;11(2).
7. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–33.
8. auspice [Internet]. [cited 2020 Apr 18]. Available from: https://nextstrain.org/narratives/ncov/sit-rep/2020-03-04
9. Bosch BJ, van der Zee R, de Haan CAM, Rottier PJM. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003 Aug;77(16):8801–11.
10. Velankar S, Alhroub Y, Best C, Caboche S, Conroy MJ, Dana JM, et al. Pdb: protein data bank in europe. Nucleic Acids Res. 2012 Jan;40(Database issue):D445-52.
11. Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, Smith CM, et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol. 2004 Dec;78(24):13600-12.
12. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020 Feb 27;
13. Jo S, Kim S, Shin DH, Kim M-S. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem. 2020 Dec;35(1):145-51.
14. 6W9C: The crystal structure of papain-like protease of SARS CoV-2 [Internet]. [cited 2020 Apr 19]. Available from: https://www.ncbi.nlm.nih.gov/Structure/pdb/6W9C
15. Kim Y, Ledrzejczak R, Maltseva NV, Endres M, Godzik A, Michalska K, et al. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. BioRxiv. 2020 Mar 3;
16. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020 Mar 30;
17. RCSB PDB - 5REK: PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102327 [Internet]. [cited 2020 Apr 19]. Available from: https://www.rcsb.org/structure/5REK
18. RCSB PDB - 6W6Y: Crystal Structure of ADP-ribose phosphatase of NSP3 from SARS CoV-2 in complex with AMP [Internet]. [cited 2020 Apr 19]. Available from: https://www.rcsb.org/structure/6W6Y
19. RCSB PDB - 6W75: 1.95 Angstrom Resolution Crystal Structure of NSP10 - NSP16 Complex from SARS-CoV-2 [Internet]. [cited 2020 Apr 19]. Available from: https://www.rcsb.org/structure/6W75
20. Griesenauer RH, Schillebeeckx C, Kinch MS. Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases. Drug Discov Today. 2019 Jan 25;24(4):1010–6.
21. Capecchi A, Awale M, Probst D, Reymond J-L. PubChem and ChEMBL beyond Lipinski. Mol Inform. 2019 Mar 7;38(5):e1900016.
22. Mumtaz A, Ashfaq UA, Ul Qamar MT, Anwar F, Gulzar F, Ali MA, et al. MPD3: a useful medicinal plants database for drug designing. Nat Prod Res. 2017 Jun;31(11):1228–36.
23. Ashfaq UA, Mumtaz A, Qamar TU, Fatima T. MAPS Database: Medicinal plant Activities, Phytochemical and Structural Database. Bioinformation. 2013 Dec 6;9(19):993–5.
24. Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, Chand RPB, Aparna SR, Mangalapandi P, et al. IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry And Therapeutics. Sci Rep. 2018 Mar 12;8(1):4329.
25. An J, Totrov M, Abagyan R. Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol Cell Proteomics. 2005 Jun;4(6):752–61.
26. Abagyan R, Kufareva I. The flexible pocketome engine for structural chemogenomics. Methods Mol Biol. 2009;575:249–79.
27. Sheridan RP, Maiorov VN, Holloway MK, Cornell WD, Gao Y-D. Drug-like density: a method of quantifying the “bindability” of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank. J Chem Inf Model. 2010 Nov 22;50(11):2029–40.
28. Abagyan R, Totrov M. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J Mol Biol. 1994 Jan 21;235(3):983–1002.
29. Neves MAC, Totrov M, Abagyan R. Docking and scoring with ICM: the benchmarking results and strategies for improvement. J Comput Aided Mol Des. 2012 Jun;26(6):675–86.
30. ICM User’s Guide: FAQ-Docking [Internet]. [cited 2020 Apr 19]. Available from: http://www.molsoft.com/icmpro/faq-docking.html
31. Yuan L, Chen Z, Song S, Wang S, Tian C, Xing G, et al. p53 degradation by a coronavirus papain-like protease suppresses type I interferon signaling. J Biol Chem. 2015 Jan 30;290(5):3172–82.
32. SID 55161740 - PubChem [Internet]. [cited 2020 Apr 17]. Available from: https://pubchem.ncbi.nlm.nih.gov/substance/55161740
33. 3E9S: A New Class Of Papain-Like ProteaseDEUBIQUITINASE Inhibitors Blocks Sars Virus Replication [Internet]. [cited 2020 Apr 17]. Available from: https://www.ncbi.nlm.nih.gov/Structure/pdb/3e9s
34. Gorbalenya AE, Eniuanes L, Ziebuhr J, Snijder EI. Nidovirales: evolving the largest RNA virus genome. Virus Res. 2006 Apr;117(1):17–37.
35. Egloff M-P, Malet H, Putics A, Heinonen M, Dutartre H, Frangeul A, et al. Structural and functional basis for ADP-ribose and poly(ADP-ribose) binding by viral macro domains. J Virol. 2006 Sep;80(17):8493–502.
36. Saikatendu KS, Joseph JS, Subramanian V, Clayton T, Griffith M, Moy K, et al. Structural basis of severe acute respiratory syndrome coronavirus ADP-ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3. Structure. 2005 Nov;13(11):1665–75.
37. Du G-J, Zhang Z, Wen X-D, Yu C, Calway T, Yuan C-S, et al. Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients. 2012 Nov 8;4(11):1679–91.
38. Kusano A, Seyama Y, Nagai M, Shibano M, Kusano G. Effects of fukinolic acid and cimicifugic acids from
Cimicifuga species on collagenolytic activity. Biol Pharm Bull. 2001 Oct;24(10):1198–201.

Ma Y, Cong W, Huang H, Sun L, Mai AH, Boonen K, et al. Identification of fukinolic acid from Cimicifuga heracleifolia and its derivatives as novel antiviral compounds against enterovirus A71 infection. Int J Antimicrob Agents. 2019 Feb;53(2):128–36.

Leung LK, Su Y, Chen R, Zhang Z, Huang Y, Chen ZY. Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J Nutr. 2001 Sep;131(9):2248–51.

Lung J, Lin Y-S, Yang Y-H, Chou Y-L, Shu L-H, Cheng Y-C, et al. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase. J Med Virol. 2020 Mar 13;

Liu C-H, Jassey A, Hsu H-Y, Lin L-T. Antiviral activities of silymarin and derivatives. Molecules. 2019 Apr 19;24(8).

Fried MW, Navarro VJ, Afadh N, Belle SH, Wahed AS, Hawke RL, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA. 2012 Jul 18;308(3):274–82.

Féher J, Lengyel G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol. 2012 Jan;13(1):210–7.

Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. “Silymarin”, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci. 2011 Jul;14(4):308–17.

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020 Mar 19;

Wang X, Xu W, Hu G, Xia S, Sun Z, Liu Z, et al. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020 Apr 7;

Lin L-T, Hsu W-C, Lin C-C. Antiviral natural products and herbal medicines. J Tradit Complement Med. 2014 Jan;4(1):24–35.

Graham RL, Sparks JS, Eckerle LD, Sims AC, Denison MR. SARS coronavirus replicase proteins in pathogenesis. Virus Res. 2008 Apr;133(1):88–100.

Dabbagh-Bazarbachi H, Clergeaud G, Quesada IM, Ortiz M, O’Sullivan CK, Fernández-Larrea JB. Zinc ionophore activity of quercetin and epigallocatechin-gallate: from Hepa 1-6 cells to a liposome model. J Agric Food Chem. 2014 Aug 13;62(32):8085–93.

Yang Y, Xiu J, Liu J, Zhang L, Li X, Xu Y, et al. Chebulagic acid, a hydrolyzable tannin, exhibited antiviral activity in vitro and in vivo against human enterovirus 71. Int J Mol Sci. 2013 May 3;14(5):9618–27.

Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci. 2017;93(7):449–63.

Ma SC, But PP, Ooi VE, He YH, Lee SH, Lee SF, et al. Antiviral amentoflavone from Selaginella sinensis. Biol Pharm Bull. 2001 Mar;24(3):311–2.

Chiang C-H, Yeh C-Y, Chung JG, Chiang I-T, Hsu F-T. Amentoflavone Induces Apoptosis and Reduces Expression of Anti-apoptotic and Metastasis-associated Proteins in Bladder Cancer. Anticancer Res. 2019 Jul;39(7):3641–9.

Hisanaga A, Ishida H, Sakao K, Sogo T, Kumamoto T, Hashimoto F, et al. Anti-inflammatory activity and molecular mechanism of Oolong tea theasinensis. Food Funct. 2014 Aug;5(8):1891–7.

Isaacs CE, Xu W, Merz G, Hillier S, Rohan L, Wen GY. Digallate dimers of (-)-epigallocatechin gallate inactive herpes simplex virus. Antimicrob Agents Chemother. 2011 Dec;55(12):5646–53.

Yadav R, Lee B, Awasthi SK. Curcumin Suppresses the Production of Pro-inflammatory Cytokine Interleukin-18 in Lipopolysaccharide Stimulated Murine Macrophage-Like Cells. Indian J Clin Biochem. 2015 Jan;30(1):109–12.

Moghadamtousi SZ, Kadir HA, Hassanarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int. 2014 Apr 29;2014:186864.

Tang J, Diao P, Shu X, Li L, Xiong L. Quercetin and Quercitrin Attenuates the Inflammatory Response and Oxidative Stress in LPS-Induced RAW264.7 Cells: In Vitro Assessment and a Theoretical Model. Biomed Res Int. 2019 Oct 28;2019:7039802.

Wu W, Li R, Li X, He J, Jiang S, Liu S, et al. Quercetin as an antiviral agent inhibits influenza A virus (IAV) entry. Viruses. 2015 Dec 25;8(1).
62. Angelucci F, Batocchi AP, Caggiula M, Frisullo G, Patanella K, Sancricca C, et al. In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients. Neuroimmunomodulation. 2006 Sep;13(2):76–81.

63. Deng L, Dai P, Ciro A, Smee DF, Djaballah H, Shuman S. Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virol. 2007 Dec;81(24):13392-402.

64. Lee E-J, Shin S-Y, Kim J-K, Woo E-R, Kim Y-M. Anti-inflammatory Effects of Amentoflavone on Modulation of Signal Pathways in LPS-stimulated RAW264.7 Cells. Bull Korean Chem Soc. 2012 Sep 20;33(9):2878–82.

65. Li F, Song X, Su G, Wang Y, Wang Z, Jia J, et al. Amentoflavone Inhibits HSV-1 and ACV-Resistant Strain Infection by Suppressing Viral Early Infection. Viruses. 2019 May 22;11(5).

66. Wang J, Shao W, Niu H, Yang T, Wang Y, Cai Y. Immunomodulatory Effects of Colistin on Macrophages in Rats by Activating the p38/MAPK Pathway. Front Pharmacol. 2019 Jun 26;10:729.

67. Mukherjee S, Siddiqui MA, Dayal S, Ayoub YZ, Malathi K. Epigallocatechin-3-gallate suppresses proinflammatory cytokines and chemokines induced by Toll-like receptor 9 agonists in prostate cancer cells. J Inflamm Res. 2014 Jun 17;7:89–101.

68. Kaihatsu K, Yamabe M, Ebara Y. Antiviral Mechanism of Action of Epigallocatechin-3-O-gallate and Its Fatty Acid Esters. Molecules. 2018 Sep 27;23(10).

69. Schmid D, Wohls F, Svoboda M, Thalhammer T, Chiba P, Moeslinger T. Aqueous extracts of Cimicifuga racemosa and phenolcarboxylic constituents inhibit production of proinflammatory cytokines in LPS-stimulated human whole blood. Can J Physiol Pharmacol. 2009 Nov;87(11):963–72.

70. Huang M-T, Liu Y, Ramji D, Lo C-Y, Ghai G, Dushenkov S, et al. Inhibitory effects of black tea theaflavin derivatives on 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and arachidonic acid metabolism in mouse ears. Mol Nutr Food Res. 2006 Feb;50(2):115–22.

71. Zu M, Yang F, Zhou W, Liu A, Du G, Zheng L. In vitro anti-influenza virus and anti-inflammatory activities of theaflavin derivatives. Antiviral Res. 2019 Jun 24;94(3):217–24.

72. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology. 2010 Feb;138(2):671–81, 681.e1.

73. Liu Y, Bao L, Xuan L, Song B, Lin L, Han H. Chebulagic acid inhibits the LPS-induced expression of TNF-α and IL-1β in endothelial cells by suppressing MAPK activation. Exp Ther Med. 2015 Jul;10(1):263–8.

74. Lin L-T, Chung C-Y, Lin T-C, Wang G-H, et al. Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC Microbiol. 2013 Aug 7;13:187.

75. Cruciani M, Parisi SG. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis. PLoS ONE. 2019 Sep 10;14(9):e0222229.

76. Tanaka T, Kameyama Y, Daikoku T, Takahashi K, Nomura N, Kurokawa M, et al. T-705 (Favipiravir) suppresses tumor necrosis factor α production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug. Acta Virol. 2017;61(1):48–55.

77. Saffronetz D, Falzarano D, Scott DP, Furuta Y, Feldmann H, Gowen BB. Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother. 2013 Oct;57(10):4673–80.

78. Elfiyik AA, Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020 Mar 25;253:117592.

79. Yuan S. Statins may decrease the fatality rate of middle east respiratory syndrome infection. MBio. 2015 Aug 11;6(4):e01120.

80. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020 Apr 17;

81. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20;105949.
Figure 1

RdRp-RNA-dependent RNA polymerase complex of SARS-CoV-2. It forms as a subsequent product of the large multiprotein replicase complex.
CHEMBL, ZINC, PUBCHEM, MPD3, MAPS

Total Selected Ligands: 3699

Searching online databases

Structure based ligand selection by molecular docking
Figure 2
Flow diagram for the search and selection of target proteins and drug ligands.

Figure 3
Sequence alignment of SARS-CoV-2 PLpro sequence (PDB code 6w9c) with SARS-CoV PLpro sequence (PDB code 3e9s). Only a segment is shown here. The sequence identity is preserved up to 82%. Greener shades represent better sequence conservation.
Superimposing of crystal structure of SARS-CoV-2 PLpro (green) (PDB code 6w9c) with the crystal structure of SARS-CoV PLpro (blue) (PDB code 3e9s). The yellow structure represents the bound ligand (5-Amino-2-Methyl-N-[(1r)-1-Naphthalen-1-Yethyl]benzamide) on SARS-CoV PLpro.
Figure 5

Selection plot for PLpro receptor site. X-axis represents the ICM score while Y-axis represents the mean force potential score.
Figure 6

Left figure shows the Theasinensin A molecule present in the receptor pocket of PLpro. Right figure shows a 2d dendrogram showing the ligand molecule in the centre, receptor pocket amino acid residues forming hydrophobic interactions with the ligand (green circles) and receptor pocket amino acid residues forming hydrogen bonds with the ligand (blue circles).
Selection plot for ADP Ribose phosphatase macro domain of NSP-3 receptor site. X-axis represents the ICM score while Y-axis represents the mean force potential score.

Figure 8
Left figure shows the Epigallocatechin molecule present in the receptor pocket of NSP-3 protein. Right figure shows a 2d dendrogram showing the ligand molecule in the centre, receptor pocket amino acid residues forming hydrophobic interactions with the ligand (green circles) and receptor pocket amino acid residues forming hydrogen bonds with the ligand (blue circles).
Figure 9

Selection plot for Mpro receptor site. X-axis represents the ICM score while Y-axis represents the mean force potential score.
Figure 10

Left figure shows the Theaflavin molecule present in the receptor pocket of Mpro protein. Right figure shows a 2d dendrogram showing the ligand molecule in the centre, receptor pocket amino acid residues forming hydrophobic interactions with the ligand (green circles) and receptor pocket amino acid residues forming hydrogen bonds with the ligand (blue circles). Histidine-41 is shown in the structural representation (arrow) forming a close hydrogen bond with the ligand.
Figure 11

Selection plot for spike protein receptor binding domain as a docking site. X-axis represents the ICM score while Y-axis represents the mean force potential score.
Figure 12

Left figure shows the Theasinensin A molecule present in the ACE-2 receptor binding domain of spike protein. Right figure shows a 2d dendrogram showing the ligand molecule in the centre, receptor pocket amino acid residues forming hydrophobic interactions with the ligand (green circles) and receptor pocket amino acid residues forming hydrogen bonds with the ligand (blue circles).
Figure 13
Selection plot for NSP-9 protein receptor binding domain as a docking site. X-axis represents the ICM score while Y-axis represents the mean force potential score.

Figure 14

Left figure shows the Epigallocatechin molecule present in the selected ligand pocket of NSP-9 protein. Right figure shows a 2d dendrogram showing the ligand molecule in the centre, receptor pocket amino acid residues forming hydrophobic interactions with the ligand (green circles) and receptor pocket amino acid residues forming hydrogen bonds with the ligand (blue circles).
Figure 15

Calculated pockets for NSP-1
Calculated pockets plotted against Drug-Likeness (DLID score) on x-axis and hydrophobicity of the pocket on y-axis while colouring is by buriedness score. The selected pocket offers the best combination of these properties.
Figure 16

Selection plot for NSP-16 protein receptor binding domain as a docking site. X-axis represents the ICM score while Y-axis represents the mean force potential score.

Figure 17

Left Figure shows the Favipiravir molecule present in the selected ligand pocket of NSP-16 protein. Right figure shows a 2d dendrogram showing the ligand molecule in the centre, receptor pocket amino acid residues forming hydrophobic interactions with the ligand (green circles) and receptor pocket amino acid residues forming hydrogen bonds with the ligand (blue circles).